Overview

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Status:
RECRUITING
Trial end date:
2026-10-31
Target enrollment:
Participant gender:
Summary
This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Shandong Suncadia Medicine Co., Ltd.